ArticleScientific reports2026
The deubiquitinase USP25 contributes to stemness and malignant progression of breast cancer by stabilizing C1ql4.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer (BC) remains one of the most aggressive and life-threatening types of female cancer. Cancer stem cells (CSCs) are closely correlated with the progression and metastasis of cancers. This study aimed to explore the role of ubiquitin-specific peptidase 25 (USP25) in breast cancer metastasis and stemness. Cell counting kit 8 (CCK-8) and 5-ethynyl-2'-deoxyuridine (EDU) assay were performed to measure cell viability and proliferation. Xenograft tumor model was established to determine in vivo growth of cancer cells. Flow cytometry was used to measure cell apoptosis. Western blot and qPCR were performed to assess the expression of apoptosis and cancer stemness biomarkers. Cancer cell self-renewal ability was analyzed by the sphere formation assay. Clinical samples were collected to measure the expression of USP25 and C1ql4 (C1q-like 4). Knockdown of USP25 suppressed the in vitro and in vivo growth of breast cancer cells and increased cell apoptosis, inhibited the self-renewal ability, downregulated the expression of cancer stemness biomarkers, and reduced the stability of C1ql4 protein, whereas overexpression of C1ql4 could reverse these effects. The clinical analysis demonstrated that USP25 and C1ql4 were highly expressed in breast cancer tissues and presented a positive correlation. Our data indicated that knockdown of USP25 suppressed the stemness growth of breast cancer cells via reducing the stability of C1ql4 protein. These findings provide USP25/C1ql4 as a potential therapeutic target for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.